Lunch Symposium (II)

Treatment for HER2 Positive Metastatic Gastric Cancer

13:00 - 13:40, L & B Cafe (醫圖咖啡廳)

Director, Division of Hematology and Oncology China Medical University Hospital 
Taichung, Taiwan

Speaker

Professor

Li-Yuan Bai
MD, MMS, PhD

白禮源 教授

Vice superintendent
National Taiwan University Hospital

Moderator

Professor

Ming-Shiang Wu

MD, PHD

明賢 教授

Abstract - Treatment for HER2 positive metastatic gastric cancer

      The prevalence of HER2 overexpression in gastric cancer is around 7-34%. The presence of HER2 overexpression is both a prognostic and a predictive factor for patients with advanced gastric adenocarcinoma. Although trastuzumab combined with chemotherapy in first line has been proved to improve the progression-free survival and overall survival for patients with metastatic gastric cancer in ToGA trial, several important issues remain: how to optimize the detection of HER2 overexpression, what the other anti-HER2 therapies are, the emergence of resistance to anti-HER2 therapy, and future prospective. In this symposium, we will discuss these clinically relevant questions.

Sponsored by

台大醫院消化外科國際論壇暨林天祐學術研討會

NTUH International Forum of Digestive Surgery & TY Lin Symposium

2020 台大醫院一般外科忘年會

2020 NTUH General Surgery Celebration Event

Multidisciplinary approach in pancreatic cancer

What

2020一般外科國際論壇暨林天祐學術研討會

When

January 18th, 2020

Where

​台大醫學院 104 講堂

Contact Us

To learn more, don’t hesitate to get in touch

  • White Facebook Icon
  • White Instagram Icon
  • White Twitter Icon
  • White LinkedIn Icon

© 2023 by TIC. Proudly created with Wix.com